Bill Cance retweeted
We’re initiating a real-world study to evaluate the clinical impact of #MCED screening among Medicare beneficiaries.
Learn more here: bit.ly/47IVxrB
Please see enclosed video providing a study overview: bit.ly/47FLRhB
Bill Cance retweeted
This past weekend at #AACRDisp23, our team presented data on multi-cancer early detection across races and ethnicities and how it can address socioeconomic disparities in receipt of cancer screening.
Bill Cance retweeted
GRAIL has been named on @FortuneMagazine's 2023 #ChangeTheWorld list. This accomplishment is only possible due to the steadfast dedication of our employees, who are working together every day to redefine the status quo of cancer detection. Read more: bit.ly/3ZB1KDu
Bill Cance retweeted
In the latest episode of our podcast #TheCancerSignal, @AICAF_Org CEO Melissa Buffalo delves into why Indigenous communities face disparities in cancer screening and care, and what can be done to address this.
🎙️Listen here: bit.ly/46eTqer
Bill Cance retweeted
Today we announced a new research collaboration with @whitmanwalker and @cancersupporthq that will evaluate multi-cancer early detection screening to increase cancer detection in underserved populations.
Learn more: bit.ly/3sp9pZ3
Bill Cance retweeted
At #ASCO23, GRAIL and @OxfordOncology will present results from SYMPLIFY, which show strong performance of multi-cancer early detection testing in people presenting with non-specific symptoms.
Learn about the exciting potential of this analysis: bit.ly/3MOOpkZ
Bill Cance retweeted
New blood tests that screen for risks of cancer and Alzheimer’s provide more information—but what do you do with that information? on.wsj.com/3Aeo4qA
Great panel discussion today. So important to obtain high quality RWD that is regulatory-grade. Thanks for a superb job moderating, Peter!
Great to be with @LhPeng, @BillCance and @DavidAgus at today's @NixonFoundation Tech in Medicine Panel. Enjoyed moderating a superb discussion on the impact of quality and real world data, patient inclusion, and talent dependencies to advance medicine. Thanks for having me!
So proud of the depth of science that underpins our transformational multi-cancer early detection test. The translational impact for patients is only beginning!
Findings from a fundamental substudy evaluating different approaches to multi-cancer early detection have been published in @Cancer_Cell. Learn how the results informed the development of our multi-cancer early detection test. bit.ly/3tHL9i5

ALT Quote from Amoolya Singh, Ph.D. Senior Vice President of Data Science and Chief Scientific Officer: "Results from the CGA study formed the basis for how we developed and refined the Galleri test -it's our origin story and the foundation of our work to transform cancer care with a simple blood test."
Bill Cance retweeted
We’re honored to have @GalleriTest included in TIME’s Best Inventions of 2022 list! #TIMEBestInventions bit.ly/3DUVGLq

ALT Cover of latest TIME magazine with the headline: The Best Inventions of 2022. 200 extraordinary innovations changing our lives, featuring a prosthetic hand with amazing precision; a color changing car; the best telescope ever; actually delicious fake steak; life-mapping artificial intelligence; diamonds made from air; a cancer-finding supertest.
Delighted to join our @ACSCAN and @AmericanCancer partners to move our efforts at earlier cancer detection forward!!
Thrilled to join our strategic partner @GrailBio while in CA. Their “wall of hope” provides inspiration and urgency to @ACSCAN & @AmericanCancer shared mission of detecting cancers earlier.
Bill Cance retweeted
#OpenAccess in the Oct 1 issue | Older age and smoking were the two most important risk factors associated with the relative and absolute 5-year risk of developing any cancer acsjournals.onlinelibrary.wi… @AlpaVPatel @BillCance @ACS_Research
Bill Cance retweeted
“We’re losing 600,000 Americans every year to this dreaded disease. But, together with the leadership of organizations like @preventcancer & the legislators being honored tonight, we can take a critical step toward ending the scourge of cancer.” - @DrJoshuaOfman @GrailBio
Great to see Dr Jacqueline Jeruss from @UMich at the @AmerSurg meeting! @ACS_Research helped launch her career and now her daughter, Sydney, is supporting #researcHERS! secure.acsevents.org/site/TR… @sandralwong
Bill Cance retweeted
Congratulations to Dr. Sue Hankinson for winning the AACR-American Cancer Society award for Research Excellence in Cancer Epidemiology and Prevention @aacr #AACR2022 @AmerCancerCMSO @AmericanCancer
Bill Cance retweeted
Great news for B-cell lymphoma patients! @AmericanCancer and @ACS_Research supports research in B-cell lymphoma and CAR T-cell treatment to help develop more effective therapies. fda.gov/drugs/resources-info…
Great to see FDA approval of the 1st targeted radiotherapy for advanced #ProstateCancer. @ACS_Research is committed to reducing PrCa burden, funding 65 PrCa grants ($26.3M) at 52 different institutions in the past 5 yrs with 18 focused on PrCa metastasis fda.gov/drugs/resources-info…
Terrific work returning people to cancer screening presented by @RachelJoung_MD at the Cancer Programs meeting today.Proud of collaboration between @AmCollSurgeons Cancer Programs and @AmericanCancer. Leveraging our strengths to amplify successes & generate metrics for next steps
Bill Cance retweeted
American Cancer Society joins Commission on Cancer in their 100 year celebration of bringing quality cancer care to patients and their families. @kathyhgoss @AmerCancerCMSO @AmericanCancer
Bill Cance retweeted
Regular physical activity & a healthy diet are 2 of the most important modifiable factors in long-term health for #CancerSurvivors. 🍅🥦⛹️♀️🏊♂️
Share this #infographic with your patients & access the latest recommendations from @AmericanCancer here: bit.ly/ACSnutrition-activity…




























